Safety and efficacy of Japanese cedar pollen sublingual immunotherapy tablet under actual use condition (interim analysis of post-marketing surveillance from 2018 to 2019)

[PE22-9] Safety and efficacy of Japanese cedar pollen sublingual immunotherapy tablet under actual use condition (interim analysis of post-marketing surveillance from 2018 to 2019)

Satoko Kobayashi, Yuriko Maekawa, Hiroko Honda, Eiji Horikawa, Chiyoko Kunishima, Noriaki Nishino (Torii Pharmaceutical Co., Ltd., Japan)

The password to see abstracts was announced to registrants by email.